Antimicrobial activity of ozenoxacin and other antimicrobials against Staphylococcus aureus strains isolated from clinical skin specimens in Japan in 2019 and 2020
Antimicrobial activity of ozenoxacin and other antimicrobials against Staphylococcus aureus strains isolated from clinical skin specimens in Japan in 2019 and 2020
复制标题
DOI：
10.1016/j.jiac.2022.08.014
复制
发表时间：
2022-10-01
影响因子：
2.2
通讯作者：
Yamasaki, Osamu
中科院分区：
文献类型：
--
作者：
Kurokawa, Ichiro;Kanayama, Shoji;Yamasaki, Osamu
由耐甲氧西林金黄色葡萄球菌 (MRSA) 引起的皮肤感染和抗菌素耐药性的蔓延是日本的一个主要问题。在这里，我们调查了金黄色葡萄球菌临床分离株对奥泽沙星 (OZNX) 的敏感性，奥泽沙星是一种在日本批准用于治疗浅表皮肤感染的外用抗菌药物。对 2019 年和 2020 年在日本分离的 110 株皮肤源性甲氧西林敏感金黄色葡萄球菌 (MSSA) 和 130 株 MRSA 菌株进行了对 OZNX 的敏感性测量。进行肉汤微量稀释法，并根据临床和实验室标准研究所（M07和M100）指南对结果进行分析。将结果与用于对抗金黄色葡萄球菌的其他抗菌剂的结果进行了比较。 OZNX对MSSA和MRSA的最低抑菌浓度（MIC）90分别为0.12和0.25μg/mL，表明OZNX表现出与其他测试的抗菌药物（如那氟沙星、夫西地酸和庆大霉素）相同或更强的抗菌活性。没有菌株表现出 OZNX 敏感性降低。值得注意的是，即使对于那氟沙星（一种类似的基于喹诺酮的局部抗菌剂）敏感性降低的菌株，也观察到 OZNX 的 MIC 较低。 OZNX 是一种高效抗菌剂，在日本用于治疗金黄色葡萄球菌引起的浅表皮肤感染，例如传染性脓疱病和相关疾病。
Skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and the spread of antimicrobial resistance are a major problem in Japan. Here, we investigated the susceptibility of S. aureus clinical isolates to ozenoxacin (OZNX), a topical antimicrobial approved for superficial skin infection treatment in Japan. Sus-ceptibility to OZNX was measured in 110 skin-derived methicillin-susceptible S. aureus (MSSA) and 130 MRSA strains isolated in 2019 and 2020 in Japan. The broth microdilution method was performed, and results were analyzed according to the Clinical and Laboratory Standard Institute (M07 and M100) guidelines. The results were compared with those of other antimicrobials used against S. aureus. The minimum inhibitory concentrations (MIC)90 of OZNX for MSSA and MRSA were 0.12 and 0.25 mu g/mL, respectively, indicating that OZNX exhibited the same or stronger antibacterial activity than that of the other antimicrobials tested, such as nadifloxacin, fucidic acid, and gentamicin. No strains exhibited reduced OZNX susceptibility. Notably, a low MIC of OZNX was observed even for strains with reduced susceptibility to nadifloxacin, a similar quinolone-based topical anti-microbial. OZNX is a highly potent antimicrobial used in Japan for superficial skin infections caused by S. aureus, such as impetigo contagiosa and related diseases.